Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1987; 9:865-871
© 1987 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Asanoi, H
Right arrow Articles by Kameyama, T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asanoi, H
Right arrow Articles by Kameyama, T

Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure

H Asanoi, S Sasayama, K Iuchi, and T Kameyama

The acute effects of OPC-8212, a newly synthesized orally effective inotropic agent, were assessed clinically. Eleven patients with moderate congestive heart failure received a single mean dose of 6.5 mg/kg body weight of the drug. Eight hours after administration, the cardiac and stroke work indexes increased by 11% (p less than 0.01) and 20% (p less than 0.005), respectively, with concomitant decreases in the diastolic pulmonary artery (25%, p less than 0.005) and right atrial pressures (33%, p less than 0.01). There were no significant changes in blood pressure or heart rate. The contractile state of the left ventricle was also assessed by the shift of the Starling curve. To construct the function curve, lower body negative pressure was used to regulate the venous return to the heart. An inotropic effect of the agent was confirmed by the shift of this function curve upward and to the left, even when an augmentation of the cardiac output was masked by the marked reduction in preload. The hemodynamic and clinical effects of OPC-8212 were encouraging and the drug appears to be promising for the treatment of congestive heart failure.


This article has been cited by other articles:


Home page
JCOHome page
A. Patnaik, E. K. Rowinsky, B. K. Tammara, M. Hidalgo, R. L. Drengler, A. M. Garner, L. L. Siu, L. A. Hammond, S. A. Felton, S. Mallikaarjun, et al.
Phase I and Pharmacokinetic Study of the Differentiating Agent Vesnarinone in Combination With Gemcitabine in Patients With Advanced Cancer
J. Clin. Oncol., December 1, 2000; 18(23): 3974 - 3985.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Focaccio, G. Peeters, M. Movsesian, R. Roden, Y. Eki, J. Krall, and M. R. Bristow
Mechanism of Action of OPC-8490 in Human Ventricular Myocardium
Circulation, February 15, 1996; 93(4): 817 - 825.
[Abstract] [Full Text]


Home page
CirculationHome page
H. Asanoi, T. Kameyama, S. Ishizaka, T. Nozawa, and H. Inoue
Energetically Optimal Left Ventricular Pressure for the Failing Human Heart
Circulation, January 1, 1996; 93(1): 67 - 73.
[Abstract] [Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement